Abstract No: WCN24-AB-926

# A real-world experience of Desidustat in Chronic Kidney Disease-anemia patients: A single centre experience

**Dr. Rohit Rungta** (MBBS, MD, DNB, MRCP)
Senior Consultant Nephrologist & Renal Transplant Physician, Medica superspeciality hospital, Kolkata

## Introduction:

- Desidustat, an oral HIF-PHI agent which helps in endogenous erythropoietin production approved for management anemia associated with CKD.
- This study was aimed to see the effects of Desidustat (Oxemia™) therapy in real-world setup.

## Material and Method:

- A real world, single centered, retrospective study
- 52 Patients with CKD anemia, with or without erythropoietin therapy were given Desidustat (Oxemia™) .
- As part of CKD Anemia treatment, patients were also receiving IV Iron ( n=20, 38.46%), and Erythropoietin (n=13, 25%).
- Monthly follow up was done to track the Hb changes.
- Dose adjustment was done according to the Hb level

| Desidustat Dose ( thrice weekly dosing) | Subjects (n, %) |
|---|---|
| 50 mg | 10, 19.23% |
| 100 mg | 41, 78.85% |
| 150 mg | 1, 1.92 % |




## Result:

- Study shown significant and stable improvement in Hb level post baseline 1.19 gm/dl ($p<0.05$, paired *t* Test), with Desidustat.
- Majority of patients remain stable with 100 mg dose, 17.3% required dose adjustments.
- Tolerability to the Desidustat therapy is very good (n=49, 94.23%),
- No adverse events observed, except 1 had constipation and throat pain.
- Lack of rigorous follow-up is a limitation of this study.







## Conclusion:

- Desidustat significantly increase the Hb in CKD Anemia without causing severe adverse drug reaction.
- More studies are requiredto assess the long term efficacy and safety of Desidustat in DD- CKD patients.

**References:**
1. Dhillon S. Desidustat: First Approval. Drugs. 2022 Jul;82(11):1207-1212. doi: 10.1007/s40265-022-01744-w. PMID: 35834123; PMCID: PMC9281218
2. Joharapurkar AA, Patel VJ, Kshirsagar SG, Patel MS, Savsani HH, Kajavadara C, Valani D, Jain MR. Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state. Curr Res Pharmacol Drug Discov. 2022 Apr 30;3:100102. doi: 10.1016/j.crphar.2022.100102. PMID: 35570856; PMCID: PMC9096675